Patent ID: 9295716
Filing Date: 2016-03-29
CPC Classification: A61K,A61L,A61P,C07K

Claim Text:
1. A method for the treatment of restenosis, wherein the restenosis is caused by neointima formation or neointimal thickening, in a patient that has been diagnosed with restenosis, wherein the method comprises: administering a therapeutically effective amount of an active agent to the patient for a period of at least 2 weeks after diagnosis of restenosis, wherein the active agent is selected from the group consisting of an Annexin A5 polypeptide, a dimer of the Annexin A5 polypeptide, the Annexin A5 polypeptide that has been PEGylated, and a dimer of the Annexin A5 polypeptide that has been PEGylated; wherein the Annexin A5 polypeptide consists of an amino acid sequence which has more than 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 and which binds to phosphatidylserine on a biological membrane to a level that is at least 80% of that displayed by human Annexin A5 having the sequence of SEQ ID NO: 1 under the same conditions.